LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development

Unified applications for clinical, regulatory, and quality streamline
end-to-end product development to increase operational efficiency

PLEASANTON, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/cloud?src=hash" target="_blank"gt;#cloudlt;/agt;–Veeva
Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader
in medical dermatology, selected Veeva
Development Cloud applications to help drive end-to-end business
processes across product development. The company will utilize the Vault
Clinical, Vault
RIM, and Vault
Quality suites to unify drug development on a single cloud platform.
With Veeva Development Cloud, LEO Pharma can bring together applications
for clinical, regulatory, and quality for even greater efficiency and
compliance throughout the product development lifecycle.

“LEO Pharma R&D has embarked on an ambitious strategy for 2025, which
will pave the way for our ambitions to continuously pioneer dermatology.
This requires that we are able to drive science globally, whilst at the
same time securing timely delivery on our pipeline,” said Kim Kjøller,
executive vice president of global research and development at LEO
Pharma. “Veeva Development Cloud gives us a unified platform that can
enable us to maximize efficiency throughout product development and
scale as we grow towards our goals. Now we will be able to streamline
product development globally and speed up delivery of new treatments to
even more patients.”

LEO Pharma aims to reach 125 million patients who have chronic and acute
skin conditions by 2025. To expand its drug development efforts, the
company has made a number of significant acquisitions and established
hubs in the United States and China. Veeva Development Cloud gives LEO
Pharma’s global teams a single source for product development
information to better maintain compliance and improve global
collaboration.

“Veeva is helping us transform our entire R&D business,” said Mika
Välilä, senior director of digital business platforms, global IT, for
LEO Pharma. “Veeva Development Cloud allows us to drive greater
consistency and productivity across product development efforts in
clinical trials, regulatory matters, and quality.”

LEO Pharma today utilizes Vault
eTMF, Vault
Submissions, and Vault
QualityDocs. In 2019, the company will add Vault
CTMS, Vault
Study Startup, Vault
Registrations, and Vault
QMS to further streamline the product development lifecycle across
regions and departments.

“LEO Pharma is a great example of how organizations are modernizing
critical business functions,” said Rik Van Mol, vice president of Veeva
Development Cloud Strategy, Europe at Veeva. “Veeva Development Cloud
gives life sciences companies the foundation to eliminate system, site,
and country silos throughout drug development.”

Additional Information
For more on Veeva Development Cloud,
visit: veeva.com/development-cloud
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems

About LEO Pharma
LEO Pharma helps people achieve healthy
skin. The company is a leader in medical dermatology with a robust R&D
pipeline, a wide range of therapies, and a pioneering spirit. Founded in
1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of
research and development to advance the science of dermatology, setting
new standards of care for people with skin conditions. LEO Pharma is
headquartered in Denmark with a global team of 5,500 people, serving 76
million patients in 130 countries. In 2018, the company generated net
sales of DKK 10,410 million. For more information, go to www.linkedin.com/company/leo-pharma or
www.leo-pharma.com.

About Veeva Systems
Veeva Systems Inc. is the leader in
cloud-based software for the global life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves more
than 700 customers, ranging from the world’s largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices throughout North America, Europe, Asia,
and Latin America. For more information, visit veeva.com.

Forward-looking Statements
This release contains
forward-looking statements, including the market demand for and
acceptance of Veeva’s products and services, the results from use of
Veeva’s products and services, and general business conditions,
particularly in the life sciences industry. Any forward-looking
statements contained in this press release are based upon Veeva’s
historical performance and its current plans, estimates, and
expectations, and are not a representation that such plans, estimates,
or expectations will be achieved. These forward-looking statements
represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.

Contacts

Lisa Barbadora
Veeva Systems
610-420-3413
[email protected]

Trine Juul Wengel
LEO Pharma
+45-72-60-8618
[email protected]